A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting

Table 1 Summary of parameter distributions for probabilities used in the PSA

Expected values of probabilities	Parameter	Expected value (standard error)	Source
		after THR	after TKR
Prophylaxis with enoxaparin
Major bleeding	par_1	0.002 (0.0006)	0.005 (0.0015)	[11, 13]
VTE event	par_2	0.035 (0.0047)	0.187 (0.0132)	[11, 13, 25]
Pre-discharge VTE¹	par_3	0.240 (0.0181)	0.530 (0.0221)	[18]
DVT	par_4	0.964 (0.0252)	0.976 (0.0120)	[11, 13, 25]
Distal DVT	par_5	0.415 (0.0677)	0.875 (0.0007)	[11, 13, 25]
Symptomatic DVT	par_6	0.167 (0.0507)	0.122 (0.0256)	[11, 13, 25]
Asymptomatic DVT becomes symptomatic	par_7	0.200 (0.1789)	0.048 (0.0466)	[20]
Non-fatal PE	par_8	0.500 (0.3536)	0.875 (0.1654)²	[11, 13, 25]
Prophylaxis with rivaroxaban
Major bleeding	par_1	0.002 (0.0006)	0.005 (0.0015)	[11, 13]
VTE event	par_9	0.010 (0.0025)	0.096 (0.0103)	[11, 13, 25]
Pre-discharge VTE¹	par_3	0.240 (0.0181)	0.530 (0.0221)	[18]
DVT	par_10	0.750 (0.1083)	0.994 (0.0089)²	[11, 13, 25]
Distal DVT	par_11	0.917 (0.0798)	0.886 (0.0358)	[11, 13, 25]
Symptomatic DVT	par_12	0.250 (0.1250)	0.099 (0.0331)	[11, 13, 25]
Asymptomatic DVT becomes symptomatic	par_7	0.200 (0.1789)	0.048 (0.0466)	[20]
Non-fatal PE	par_13	0.875 (0.1654)²	0.500 (0.5000)²	[11, 13, 25]

PSA = probabilistic sensitivity analysis, VTE = venous thromboembolism, DVT = deep vein thrombosis, PE = pulmonary embolism.
¹Values are independent of prophylactic drug.²If the point estimate yielded to 0 or 1, half an event was added or subtracted to receive reasonable distributions for probabilistic sensitivity analysis.

ISSN: 1472-6963